phenobarbital with belladonna alkaloids- phenobarbital, hyoscyamine sulfate, atropine sulfate, scopolamine hydrobromide tablet
bryant ranch prepack - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i), scopolamine hydrobromide (unii: 451ifr0gxb) (scopolamine - unii:dl48g20x8x) - based on a review of this drug by the national academy of sciences-national research council and/or other information, fda has classified the indications as follows: "possibly" effective: for use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. may also be useful as adjunctive therapy in the treatment of duodenal ulcer. final classification of the less-than-effective indications requires further investigation. it has not been shown conclusively whether anticholinergic/antispasmodic drugs aid in the healing of a duodenal ulcer, decrease the rate of recurrences or prevent complications. - glaucoma; - obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); - obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); - paralytic ileus, intestinal atony of the elderly or debilitated patient; - unstable cardiovascular status in acute hemorrhage; - se
phenobarbital with belladonna alkaloids - mint- phenobarbital, hyoscyamine sulfate, atropine sulfate, scopolamine hydrobromide e
bryant ranch prepack - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i), scopolamine hydrobromide (unii: 451ifr0gxb) (scopolamine - unii:dl48g20x8x) - based on a review of this drug by the national academy of sciences-national research council and/or other information, fda has classified the indications as follows: "possibly" effective: for use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. may also be useful as adjunctive therapy in the treatment of duodenal ulcer. final classification of the less-than-effective indications requires further investigation. it has not been shown conclusively whether anticholinergic/antispasmodic drugs aid in the healing of a duodenal ulcer, decrease the rate of recurrences or prevent complications. - glaucoma; - obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); - obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); - paralytic ileus, intestinal atony of the elderly or debilitated patient; - unstable cardiovascular status in acute hemorrhage; - se
phenobarbital with belladonna alkaloids - grape- phenobarbital, hyoscyamine sulfate, atropine sulfate, scopolamine hydrobromide
bryant ranch prepack - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i), scopolamine hydrobromide (unii: 451ifr0gxb) (scopolamine - unii:dl48g20x8x) - based on a review of this drug by the national academy of sciences-national research council and/or other information, fda has classified the indications as follows: "possibly" effective: for use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. may also be useful as adjunctive therapy in the treatment of duodenal ulcer. final classification of the less-than-effective indications requires further investigation. it has not been shown conclusively whether anticholinergic/antispasmodic drugs aid in the healing of a duodenal ulcer, decrease the rate of recurrences or prevent complications. - glaucoma; - obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); - obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); - paralytic ileus, intestinal atony of the elderly or debilitated patient; - unstable cardiovascular status in acute hemorrhage; - se
kimite- scopolamine patch, extended release
oasis trading - scopolamine (unii: dl48g20x8x) (scopolamine - unii:dl48g20x8x) - relieve the vomiting, nausea, dizziness, anorexia, and other symptoms resulted from sickness of cars, ships, airplanes, trains and other means of transport ■ tear the protective layer, adhere the adhesive layer to the navel or the back of your ears ■ one/ two patch per time, accoding to your body condition ■ attach 10 minutes before the travel, the effect will last about 1-3 days
scopolamine transdermal system
viatris limited - hyoscine 1.45mg equivalent to scopolamine; - transdermal patch - active: hyoscine 1.45mg equivalent to scopolamine excipient: = pigmented poylethylene/polyester film (mediflex® 1501) = transparent fluoropoylmer coated polyester release liner (scotchpak 1022 or scotchpak 9709) no tox ink brown- fgn4476 polypropylene povidone silicone adhesive - for the prevention of symptoms of motion sickness, such as nausea, vomiting and vertigo, which can occur when travelling.
buscopan compositum solution for injection
boehringer ingelheim ltd - butylscopolamine bromide, metamizole - solution for injection - not currently available - butylscopolamine and analgesics - cattle, dogs, horses - n.s.a.i.d.
ax pharmaceutical corp- n-butylscopolammonium bromide powder
ax pharmaceutical corp - butylscopolamine bromide (unii: 0gh9jx37c8) (butylscopolamine - unii:2z3e1of81v) -
scopoderm
baxter healthcare ltd - hyoscine 1.5mg (supplied as hyoscine (scopolamine) hydrobromide trihydrate); - transdermal patch - 1mg/72 hours - active: hyoscine 1.5mg (supplied as hyoscine (scopolamine) hydrobromide trihydrate) - the prevention of symptoms of motion sickness, such as nausea, vomiting and vertigo, which can occur when traveling.
phenohytro- phenobarbital, hyoscyamine sulfate, atropine sulfate, and scopolamine hydrobromide elixir
winder laboratories llc - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i), scopolamine hydrobromide (unii: 451ifr0gxb) (scopolamine - unii:dl48g20x8x) - based on the national academy of sciences-national research council's review of this drug and/or other information, fda has classified the following indications as "possibly" effective: for use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. may also be useful as adjunctive therapy in the treatment of duodenal ulcer. it has not been shown conclusively whether anticholinergic / antispasmodic drugs aid in the healing of a duodenal ulcer, decrease the rate of recurrences, or prevent complications. phenohytro® elixir is contraindicated in patients with known hypersensitivity to any of the ingredients. phenobarbital is contraindicated in patients with acute intermittent porphyria and in those patients in which phenobarbital produces restlessness and/or excitement. phenohytro® elixir is also contraindicated in patients with glaucoma, obstructive uropathy; paralytic ileus; myasthenia gravis; intestinal atony; unstable card
donnatal extentabs- phenobarbital, hyoscyamine sulfate, atropine sulfate, scopolamine hydrobromide tablet, film coated, extended
pbm pharmaceuticals, inc - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i), scopolamine hydrobromide (unii: 451ifr0gxb) (scopolamine - unii:dl48g20x8x) - phenobarbital 48.6 mg - based on a review of this drug by the national academy of sciences - national research council and/or other information, fda has classified the following indications as “possibly” effective: for use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. may also be useful as adjunctive therapy in the treatment of duodenal ulcer. it has not been shown conclusively whether anticholinergic/antispasmodic drugs aid in the healing of a duodenal ulcer, decrease the rate of recurrences or prevent complications. glaucoma, obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus, intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis especially if complicated by toxic megacolon; myasthenia gravis; hia